{"entity":{"id":"shanu-modi","kind":"person","name":"Shanu Modi","aka":[],"tldr":"Led DESTINY-Breast01 and DESTINY-Breast04, the trials that created the HER2-low category and opened T-DXd to most breast cancers.","summary":"Shanu Modi was lead investigator of DESTINY-Breast01, the study that won trastuzumab deruxtecan its first approval, and of DESTINY-Breast04, which showed the ADC halves the risk of progression in HER2-low disease previously treated as HER2-negative. That trial redefined breast cancer classification and extended ADC therapy to roughly half of all patients. She continues to lead ADC trials at MSKCC.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Modi%20S%5BAuthor%5D%20trastuzumab%20deruxtecan"}],"tags":["breast","adc","her2-low"],"related":[],"cancers":["breast-her2-positive","breast-hr-positive","tnbc"],"sections":[],"technologies":["adc"],"targets":["her2"],"drugs":["trastuzumab-deruxtecan"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["destiny-breast04"],"people":[],"bottlenecks":[],"keyPapers":["paper-destiny-breast04-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Breast Medical Oncologist, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["HER2-directed therapy","HER2-low breast cancer","Antibody-drug conjugates"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Modi%20S%5BAuthor%5D%20trastuzumab%20deruxtecan"}],"papers":[{"title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer (DESTINY-Breast01)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa1914510"},{"title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer (DESTINY-Breast04)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2203690"}],"orcid":"0000-0001-6427-7373"},"route":"/people/shanu-modi/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"drug":[{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"trial":[{"id":"destiny-breast04","kind":"trial","name":"DESTINY-Breast04","route":"/trials/destiny-breast04/"}],"paper":[{"id":"paper-destiny-breast04-nejm-2022","kind":"paper","name":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","route":"/key-papers/paper-destiny-breast04-nejm-2022/"}]}}